Cell & Gene Therapy

Cell & Gene Therapy

Marken has a unique cell and gene therapy offering, supporting both clinical and commercial therapies with multi-dimensional logistics and global cryogenic network to deliver tomorrow’s advanced therapy lifelines.

Supporting image

Go beyond with us

Our ever-evolving portfolio includes secure, closed loop supply chain services, end-to-end visibility through data-driven tracking solutions and 24/7 cell and gene control tower monitoring oversight. As the leading partner to safeguard these ultra-sensitive, time and temperature-critical treatments, we go beyond cell and gene orchestration to support patients who rely on us to anticipate, innovate and deliver.

Supporting image

Related resources

Marken seamlessly orchestrates distribution of first commercial CAR-T therapy drug product from USA to Japan

28 April 2023

Marken successfully orchestrated the distribution of the first commercial CAR-T therapy drug product from the USA to a hospital in…

Marken’s 24/7 Cell & Gene Control Tower Provides Agile Solution for Critical Shipments

9 February 2023

Marken’s Cell and Gene Control Tower re-routed six critical shipments of CAR-T drug products from Amsterdam to the UK and…

Operational Excellence Overcomes Obstacles to Deliver Critical Autologous Cell Therapy

9 February 2023

Marken utilized operational excellence to deliver a critical autologous cell therapy. Although there were many challenges, Marken was able to…

Marken Successfully Safeguards the Viability of Pharmaceutical Samples Within 42 Hours

4 January 2023

The distribution of critical cell samples requires an agile strategy with contingency planning and regulatory expertise to ensure seamless delivery…

Happy Holidays from Marken

21 December 2022

At Marken, we are passionate about patients – always finding a way to deliver for our clients – on-time, within…

Marken Overcomes Multiple Obstacles To Successfully Deliver Critical Stem Cell Samples Across The Globe

9 December 2022

Stem cell samples require extremely tight 24-hour turnaround times in order to be modified and processed for critical cell therapy…

Personalized Medicine Requires Complex Supply Chains: Marken

26 July 2021

Outsourcing-Pharma and Nina Vas, Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, discuss the specific requirements involved…

Evaluating a Clinical Supply Chain Partner to Meet Your Vaccine Trial Needs

23 April 2021

It is essential for pharmaceutical companies to evaluate many factors when choosing a clinical supply chain partner. With today’s global…

Decentralized Trials Call for Supply Chain Flexibility: Marken

8 April 2021

Outsourcing-Pharma and Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, Nina Vas, and Senior Director of Global…

Marken Successfully Ensures On-Time Release Of CAR-T Cell Treatment In Spain

18 March 2021

Overcoming Brexit challenges to coordinate time-sensitive shipments About Marken Marken is a wholly owned subsidiary of UPS and is a…

Marken Makes It Happen COVID-19

13 October 2020

In these unprecedented times, we are coming together to achieve one shared goal: to beat COVID-19. The Marken team is…

Solving Complexities In the Era Of Personalized Medicine

14 October 2019

Cell and gene therapies are fundamentally different than traditional medicines, from the patient and product journeys to the systems and…

View more

Delivering What Matters

Marken Logo

Understanding why we must adapt, continuously asking ourselves how we can change what matters is how we keep on delivering it.